share_log

Tharimmune | 10-Q: Q2 2024 Earnings Report

Tharimmune | 10-Q: Q2 2024 Earnings Report

Tharimmune | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/10 03:12

Moomoo AI 已提取核心信息

Tharimmune reported financial results for Q2 2024, with a net loss of $2.3 million compared to $2.3 million in Q2 2023. Research and development expenses were $1.0 million, while general and administrative expenses totaled $1.4 million. The company ended the quarter with $7.9 million in cash and cash equivalents, down from $10.9 million at the end of 2023.The company made significant clinical progress, reporting positive Phase 1 results for TH104 showing consistent pharmacokinetic profiles and safety across buccal and intravenous administration. The FDA provided positive Type C meeting feedback supporting a 505(b)(2) approval pathway for TH104's Phase 2 trial in chronic pruritus patients with primary biliary cholangitis, planned for late 2024.In June 2024, Tharimmune strengthened its financial position through a $2.1 million private placement offering and established a $1.65 million ATM facility. The company also expanded its pipeline through new licensing agreements with Enkefalos Biosciences for blood-brain barrier penetrating antibody technology and continued development of novel therapeutic candidates targeting HER2/HER3 and PD-1 for immuno-oncology applications.
Tharimmune reported financial results for Q2 2024, with a net loss of $2.3 million compared to $2.3 million in Q2 2023. Research and development expenses were $1.0 million, while general and administrative expenses totaled $1.4 million. The company ended the quarter with $7.9 million in cash and cash equivalents, down from $10.9 million at the end of 2023.The company made significant clinical progress, reporting positive Phase 1 results for TH104 showing consistent pharmacokinetic profiles and safety across buccal and intravenous administration. The FDA provided positive Type C meeting feedback supporting a 505(b)(2) approval pathway for TH104's Phase 2 trial in chronic pruritus patients with primary biliary cholangitis, planned for late 2024.In June 2024, Tharimmune strengthened its financial position through a $2.1 million private placement offering and established a $1.65 million ATM facility. The company also expanded its pipeline through new licensing agreements with Enkefalos Biosciences for blood-brain barrier penetrating antibody technology and continued development of novel therapeutic candidates targeting HER2/HER3 and PD-1 for immuno-oncology applications.
Tharimmune公布了2024年第二季度的财务结果，净亏损为230万，较2023年第二季度的230万持平。研发费用为100万，管理费用总计140万。公司在季度末拥有790万的现金及现金等价物，低于2023年底的1090万。公司取得了显著的临床进展，报告TH104的I期结果积极，在口腔给药和静脉给药中显示出一致的药代动力学特征和安全性。FDA提供了积极的C类会议反馈，支持TH104在慢性瘙痒患者中进行505(b)(2)批准路径的II期试验，计划于2024年底进行。2024年6月，Tharimmune通过210万的定向增发加强了其财务状况，并建立了165万的ATM融资设施。公司还通过与Enkefalos Biosciences的新许可协议扩展其产品线，针对血脑屏障穿透抗体科技，并继续开发针对HER2/HER3和PD-1的创新治疗候选药物，用于免疫肿瘤学应用。
Tharimmune公布了2024年第二季度的财务结果，净亏损为230万，较2023年第二季度的230万持平。研发费用为100万，管理费用总计140万。公司在季度末拥有790万的现金及现金等价物，低于2023年底的1090万。公司取得了显著的临床进展，报告TH104的I期结果积极，在口腔给药和静脉给药中显示出一致的药代动力学特征和安全性。FDA提供了积极的C类会议反馈，支持TH104在慢性瘙痒患者中进行505(b)(2)批准路径的II期试验，计划于2024年底进行。2024年6月，Tharimmune通过210万的定向增发加强了其财务状况，并建立了165万的ATM融资设施。公司还通过与Enkefalos Biosciences的新许可协议扩展其产品线，针对血脑屏障穿透抗体科技，并继续开发针对HER2/HER3和PD-1的创新治疗候选药物，用于免疫肿瘤学应用。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Checkpoint Therapeutics
    CKPT
    -- 3.980
    Protagonist Therapeutics
    PTGX
    -- 55.950
    Mineralys Therapeutics
    MLYS
    -- 14.960
    Trevi Therapeutics
    TRVI
    -- 6.070
    AEON Biopharma
    AEON
    -- 0.920
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    两会召开：中概股走势将如何演变？
    🎙️讨论 1. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 2. 你预计“两会”期间出台的政策将如何影响你的投资策略？ 3. 你对“两会”期间股市的波动性有何预期？ 展开
    中国两会：会议前后股票价格走势的主要要点